compounding semaglutide fda for weight loss | Blog Novo Nordisk asks FDA to

Managing Nausea and Digestive Symptoms With Semaglutide Nausea is one of the most common side effects in the first 48 weeks of semaglutide therapy, occurring in roughly 2530% of patients during dose escalation phases

We help patients understand: How these medicines work Whether a GLP-1 pill or injection may suit their health What to expect during treatment How to manage side effects safely Which long-term approach fits their lifestyle Our goal is simple: to offer practical, evidence-based care so you feel confident in every step of your weight-management journey

Stick with it for at least 4 weeks

Clinical studies show that patients typically lose 10-20% of their body weight over several months with GLP-1 therapy